Description

Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) [1][2][3][4].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)–COVID-19-immunoregulation–C117H181N34O32PS.xC2HF3O2—-[1]Aikaterini Thanou, et al. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. |[2]Sean Robinson, et al. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front Immunol. 2021 Jul 16;12:654701.|[3]Robert Zimmer, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013 Nov;72(11):1830-5.|[4]Baihui Li, et al. Rescue of autophagy and lysosome defects in salivary glands of MRL/lpr mice by a therapeutic phosphopeptide. J Autoimmun. 2018 Jun;90:132-145.—-N/A–98.89–O=C(C(F)(F)F)O.OC(C=C1)=CC=C1C[C@H](NC([C@H](C(C)C)NC([C@H](CCSC)NC([C@@H](NC([C@H]([C@@H](C)CC)NC([C@@H](N)CCCNC(N)=N)=O)=O)CC2=CN=CN2)=O)=O)=O)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](COP(O)(O)=O)C(NCC(N[C@@H](CCCCN)C(N3[C@@H](CCC3)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@H](C(N[C@@H](C)C(N[C@H](C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@H](C(O)=O)CC4=CC=C(C=C4)O)=O)=O)=O)CC5=CC=CC=C5)=O)=O)CC6=CC=C(C=C6)O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology–DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)–Autophagy—-Autophagy–Peptides